Hideaki Nagaya

In Vitro Antagonistic Properties of a New Angiotensin Type 1 Receptor Blocker, Azilsartan, in Receptor Binding and Function Studies

Mami Ojima, Hideki Igata, Masayuki Tanaka et al. · Journal of Pharmacology and Experimental Therapeutics · 2010 · 146 citations

Antisecretory and antiulcer activities of a novel proton pump inhibitor AG-1749 in dogs and rats.

Hiroshi Satoh, Nobuhiro Inatomi, Hideaki Nagaya et al. · Journal of Pharmacology and Experimental Therapeutics · 1989 · 144 citations

Possible mechanism for the inhibition of gastric (H+ + K+)-adenosine triphosphatase by the proton pump inhibitor AG-1749.

Hideaki Nagaya, Hiroya Satoh, Kentaro Kubo et al. · Journal of Pharmacology and Experimental Therapeutics · 1989 · 107 citations

Possible mechanism for the inhibition of acid formation by the proton pump inhibitor AG-1749 in isolated canine parietal cells.

Hideaki Nagaya, H Satoh, Yoshitaka Maki · Journal of Pharmacology and Experimental Therapeutics · 1990 · 93 citations

Antihypertensive, insulin-sensitising and renoprotective effects of a novel, potent and long-acting angiotensin II type 1 receptor blocker, azilsartan medoxomil, in rat and dog models

Keiji Kusumoto, Hideki Igata, Mami Ojima et al. · European Journal of Pharmacology · 2011 · 53 citations

Hypertension, Medicine, Antihypertensive Therapy +9